Myriad Genetics at strong buy rating from JMP

Myriad Genetics, Inc. was reiterated at strong buy with an increased price target to $33 from $29 by JMP Securities analyst Charles C. Duncan. Myriad Genetics reported quarterly results Tuesday that beat the analyst's and consensus revenues and net loss estimates with higher-than-anticipated predictive medicine revenue. JMP raised its 2006 and 2007 total revenue expectations to $114.8 million and $135 million from $108 million and $125 million, respectively. Shares of the Salt Lake City biopharmaceutical company were up $1.54, or 6.08%, at $26.86 on volume of 640,317 shares versus the three-month running average of 408,785 shares. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.